Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MindBio Therapeutics Corp. C.MBIO

Healthcare Biotechnology
MindBio Therapeutics Corp is a pioneering clinical stage biotechnology company that specializes in developing psychedelic microdosing treatments for mental health conditions. MindBio has obtained government and regulatory approvals for at-home LSD microdosing in clinical trials, making it the only organization in the world to do so.

Recent & Breaking News (CSE:MBIO)

Mindbio Therapeutics Nominated for Company of the Year in Industry Awards

Accesswire October 26, 2023

MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001

Accesswire October 24, 2023

Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials

Accesswire October 5, 2023

Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research

Accesswire September 14, 2023

MindBio announces major genetic discovery in microdosing research

Jonathon Brown September 5, 2023

MindBio Therapeutics Announces Major Genetic Discovery in Microdosing Research

Accesswire September 5, 2023

Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression

Accesswire August 24, 2023

World’s first psychedelic microdosing home trials ready for Phase 2

Jonathon Brown August 18, 2023

Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials

Accesswire August 18, 2023

MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress

Accesswire July 25, 2023

MindBio Therapeutics World First Phase 2 Take-Home LSD-Microdosing Clinical Trial in Patients with Major Depressive Disorder Begins Pre-Screening Participants

Accesswire July 19, 2023

Psychedelics stock’s LSD clinical trial reports sleep quality breakthrough

Jonathon Brown June 14, 2023

MindBio Therapeutics Breakthrough Discovery in Microdosing Clinical Trial Reveals Significant Positive Effects on Quality Of Sleep

Accesswire June 14, 2023

MindBio Therapeutics Co-Founders Appear in Leading Australian Financial News Publication Ahead of Medicinal Psychedelics Legalisation in Australia

Accesswire June 9, 2023

MindBio Therapeutics CEO To Present at Emerging Equities Life Sciences VIP Event and Showcase MindBio's Research at Upcoming MAPS Psychedelics Science Conference in Colorado

Accesswire June 6, 2023

MindBio Therapeutics CEO Demonstrates how 1 Million Microdoses of LSD can Potentially be Used to Treat Depression at Scale

Accesswire May 30, 2023

Psychedelics stock moving forward with pioneering LSD clinical trial

Trevor Abes  May 23, 2023

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

Accesswire May 23, 2023

MindBio Therapeutics Chief Executive Officer Issues Letter to Shareholders Discussing the Company's Growth Plans

Accesswire May 16, 2023

MindBio Therapeutics Phase 2 Clinical Trial Has Received Ethics Approval for World First Take-Home LSD-Microdosing Trials in Cancer Patients Experiencing Emotional Distress

Accesswire May 11, 2023